Broadfin Capital’s Epizyme, Inc EPZM Stock Holding History

Broadfin Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-100,000	Closed	-$2.08M	–	91
2013 Q4	$2.08M	Buy	+100,000	New	+$2.9M	0.27%	56

Other funds holding EPZM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Broadfin Capital's EPZM Position: Q1 2014 in Review

Broadfin Capital sold out of Epizyme, Inc (EPZM) in Q1 2014, closing a stake of 100,000 shares — an estimated $2.08M sold.

Broadfin Capital first reported a position in EPZM in Q4 2013 and held it in 1 quarter. The position peaked at $2.08M in Q4 2013. 75 funds tracked by Wall St. Rank hold EPZM as of Q1 2014.

Broadfin Capital reported no remaining Epizyme, Inc position as of Q1 2014 after selling out during the quarter.
Broadfin Capital sold 100,000 Epizyme, Inc shares in Q1 2014, an estimated $2.08M.
Broadfin Capital first reported a position in Epizyme, Inc in Q4 2013 and held it in 1 quarter.
Broadfin Capital's Epizyme, Inc position peaked at $2.08M in Q4 2013.
75 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2014.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.